<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="157995">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01042795</url>
  </required_header>
  <id_info>
    <org_study_id>HUM00030127</org_study_id>
    <nct_id>NCT01042795</nct_id>
  </id_info>
  <brief_title>Trial of Adjuvant Sutent for Patients With High Risk Urothelial Carcinoma After Neoadjuvant Chemotherapy and Cystectomy</brief_title>
  <official_title>Phase II Trial of Adjuvant Sutent for Patients With High Risk Urothelial Carcinoma After Neoadjuvant Chemotherapy and Cystectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Michigan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether sutent (sunitinib)is effective in
      preventing tumor recurrence in patients with high risk bladder cancer who have previously
      had chemotherapy and cystectomy (bladder removal).

      A 4 month supply of the drug is given to patients beginning 2-3 months after bladder
      removal. The patients are followed up to 2 years.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    STudy closed due to poor accrual
  </why_stopped>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease Free Survival</measure>
    <time_frame>2- year</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Urothelial Carcinoma</condition>
  <condition>Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>Continuous Daily Dosing of Sunitinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sunitinib</intervention_name>
    <description>Sunitinib 37.5 mg daily X 16 weeks</description>
    <arm_group_label>Continuous Daily Dosing of Sunitinib</arm_group_label>
    <other_name>Sutent</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologic diagnosis of bladder carcinoma (&gt;50% urothelial carcinoma)

          -  Prior treatment with at least one cycle of platin-based neoadjuvant chemotherapy

          -  Prior treatment with radical cystectomy revealing pT3NxM0 or pTanyN+M0

          -  ECOG performance status of 0-1 (Appendix 2).

          -  No evidence of metastases within 4 weeks of registration

          -  Adequate organ and marrow function obtained within 14 days of registration

        Exclusion Criteria:

          -  Severe or uncontrolled acute or chronic medical or psychiatric condition

          -  Prior antiangiogenic therapy

          -  Prior pelvic radiation for bladder cancer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <lastchanged_date>January 17, 2013</lastchanged_date>
  <firstreceived_date>January 5, 2010</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Michigan</investigator_affiliation>
    <investigator_full_name>Cheryl Lee</investigator_full_name>
    <investigator_title>Associate Professor of Urology</investigator_title>
  </responsible_party>
  <keyword>sunitinib</keyword>
  <keyword>bladder neoplasm</keyword>
  <keyword>adjuvant treatment</keyword>
  <keyword>disease free survival</keyword>
  <keyword>Patients with extravesical tumor (pT2-4,Nany, M0 or pTanyN+M0) after cystectomy and platin-based neoadjuvant chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sunitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
